BioMarin Discloses Significant ROCTAVIAN Asset Write-Down and Preliminary FY25 Results

summarizeSummary

BioMarin Pharmaceutical Inc. announced preliminary full-year 2025 financial results, including total revenues at the high end of guidance, but also disclosed a substantial asset write-down for ROCTAVIAN, negatively impacting Non-GAAP EPS.

check_boxKey Events

• ROCTAVIAN Asset Write-Down

  BioMarin expects a $230 million to $260 million asset write-down for ROCTAVIAN in Q4 2025, with approximately $120 million to $125 million (or $(0.60) to $(0.64) per share) impacting Non-GAAP Diluted EPS.

• Preliminary FY25 Revenues

  The company estimates approximately $3.2 billion in total revenues for the year ended December 31, 2025, which is at the high end of its previous guidance range.

• VOXZOGO Performance

  VOXZOGO sales are estimated at approximately $920 million for FY 2025, falling within the prior guidance range.

• 2026 Guidance Impact

  ROCTAVIAN revenue will be excluded from BioMarin's 2026 financial guidance, indicating a reduced focus or expectation for the product's future contribution.

auto_awesomeAnalysis

The disclosure of a $230 million to $260 million asset write-down for ROCTAVIAN, which was not previously included in guidance, is a significant negative development. This write-down indicates a material impairment of the product's value and future prospects. While overall revenues for 2025 were strong, the ROCTAVIAN write-down will materially reduce Non-GAAP Diluted EPS and signals a strategic shift away from the product, as its revenue will be excluded from 2026 guidance. Investors should monitor the company's full Q4 and FY25 earnings report for further details on the write-down and its implications for future product strategy and profitability.